Taysha Gene Therapies
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TSHA and other ETFs, options, and stocks.About TSHA
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing.
CEOSean P. Nolan
CEOSean P. Nolan
Employees73
Employees73
HeadquartersDallas, Texas
HeadquartersDallas, Texas
Founded2019
Founded2019
Employees73
Employees73
TSHA Key Statistics
Market cap1.23B
Market cap1.23B
Price-Earnings ratio-12.89
Price-Earnings ratio-12.89
Dividend yield—
Dividend yield—
Average volume2.75M
Average volume2.75M
High today$4.60
High today$4.60
Low today$4.45
Low today$4.45
Open price$4.54
Open price$4.54
Volume452.01K
Volume452.01K
52 Week high$6.02
52 Week high$6.02
52 Week low$1.05
52 Week low$1.05
Stock Snapshot
Taysha Gene Therapies(TSHA) stock is priced at $4.48, giving the company a market capitalization of 1.23B. It carries a P/E multiple of -12.89.
On 2026-03-18, Taysha Gene Therapies(TSHA) stock moved within a range of $4.45 to $4.60. With shares now at $4.48, the stock is trading +0.7% above its intraday low and -2.6% below the session's peak.
Trading activity shows a volume of 452.01K, compared to an average daily volume of 2.75M.
Over the past 52 weeks, Taysha Gene Therapies(TSHA) stock has traded between a high of $6.02 and a low of $1.05.
Over the past 52 weeks, Taysha Gene Therapies(TSHA) stock has traded between a high of $6.02 and a low of $1.05.
Analyst ratings
100%
of 14 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own TSHA. This list is generated using Robinhood data, and it’s not a recommendation.